Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

Summary

This is a single-center, randomized, double-blind, placebo-controlled, sequential group study. The primary objective of this study is to assess the tolerability and safety of single doses of ME1100 inhalation solution (orally inhaled arbekacin). The secondary objective is to determine the systemic exposure to, and urinary elimination of, ME1100.

Timeline

Start

2013-07

Primary completion

2013-12

Completion

—

Drugs

Indications

No indication recorded.